HERTFORDSHIRE, England and
PITTSBURGH, July 23, 2015 /PRNewswire/ -- Mylan N.V.
(NASDAQ: MYL) today acknowledged the exercise of the full call option by Stichting Preferred
Shares Mylan, an independent foundation ("stichting")
incorporated under the laws of the
Netherlands (the "Foundation"). The Foundation notified
Mylan that it has exercised its call option to acquire 488,388,431
Mylan preferred shares pursuant to the Call Option Agreement, dated
April 3, 2015, between Mylan and the
Foundation.
ABOUT MYLAN
Mylan is a global pharmaceutical
company committed to setting new standards in healthcare. Working
together around the world to provide 7 billion people access to
high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not
what's easy; and impact the future through passionate global
leadership. We offer a growing portfolio of around 1,400 generic
pharmaceuticals and several brand medications. In addition, we
offer a wide range of antiretroviral therapies, upon which nearly
50% of HIV/AIDS patients in developing countries depend. We also
operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in about 145 countries
and territories. Our workforce of approximately 30,000 people is
dedicated to creating better health for a better world, one person
at a time. Learn more at mylan.com.
ADDITIONAL INFORMATION
This communication is neither
an offer to purchase nor an offer to sell any securities. In
connection with Mylan N.V.'s ("Mylan") proposal to acquire Perrigo
Company plc ("Perrigo"), Mylan has filed a preliminary proxy
statement on Schedule 14A on May 5,
2015 (which preliminary proxy statement was amended on
June 19, 2015 and July 16, 2015, the "Preliminary Proxy Statement")
in anticipation of its extraordinary general meeting. This
communication is not intended to be, and is not, a substitute for
such filing or for any other document that Mylan may file with the
Securities and Exchange Commission ("SEC") in connection with
Mylan's proposed acquisition of Perrigo (the "Perrigo Proposal").
INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE DOCUMENTS FILED
WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY (IF AND WHEN THEY
BECOME AVAILABLE) BEFORE MAKING AN INVESTMENT DECISION BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION. Such documents will be
available free of charge through the website maintained by the SEC
at www.sec.gov or by directing a request to Mylan at 724-514-1813
or investor.relations@mylan.com. Any materials filed by Mylan
with the SEC that are required to be mailed to shareholders will
also be mailed to such shareholders.
PARTICIPANTS IN SOLICITATION
This communication is
not a solicitation of a proxy from any investor or shareholder.
However, Mylan and certain of its directors, executive officers and
other members of its management and employees may be deemed to be
participants in the solicitation of proxies in connection with the
Perrigo Proposal under the rules of the SEC. Information regarding
Mylan's directors and executive officers may be found in Mylan
Inc.'s Annual Report on Form 10-K for the fiscal year ended
December 31, 2014, which was filed
with the SEC on March 2, 2015 and
amended on April 30, 2015, as well as
in the Preliminary Proxy Statement. These documents can be
obtained free of charge from the sources indicated above.
Additional information regarding the interests of these
participants, which may, in some cases, be different than those of
Mylan's shareholders generally, will also be included in the
materials that Mylan intends to file with the SEC when they become
available.
FORWARD-LOOKING STATEMENTS
This communication
contains "forward-looking statements." Such forward-looking
statements may include, without limitation, statements about the
Perrigo Proposal, Mylan's acquisition (the "EPD Transaction") of
Mylan Inc. and Abbott Laboratories' non-U.S. developed markets
specialty and branded generics business (the "EPD Business"), the
benefits and synergies of the Perrigo Proposal or EPD Transaction,
future opportunities for Mylan, Perrigo, or the combined company
and products, and any other statements regarding Mylan's,
Perrigo's, or the combined company's future operations, anticipated
business levels, future earnings, planned activities, anticipated
growth, market opportunities, strategies, competition, and other
expectations and targets for future periods. These may often be
identified by the use of words such as "will," "may," "could,"
"should," "would," "project," "believe," "anticipate," "expect,"
"plan," "estimate," "forecast," "potential," "intend," "continue,"
"target" and variations of these words or comparable words. Because
forward-looking statements inherently involve risks and
uncertainties, actual future results may differ materially from
those expressed or implied by such forward-looking statements.
Factors that could cause or contribute to such differences include,
but are not limited to: uncertainties related to the Perrigo
Proposal, including as to the timing of the offer and compulsory
acquisition, whether Perrigo will cooperate with Mylan and whether
Mylan will be able to consummate the offer and compulsory
acquisition, whether Mylan shareholders will provide the requisite
approvals for the Perrigo Proposal, the possibility that competing
offers will be made, the possibility that the conditions to the
consummation of the offer will not be satisfied, and the
possibility that Mylan will be unable to obtain regulatory
approvals for the offer and compulsory acquisition or be required,
as a condition to obtaining regulatory approvals, to accept
conditions that could reduce the anticipated benefits of the offer
and compulsory acquisition; the ability to meet expectations
regarding the accounting and tax treatments of a transaction
relating to the Perrigo Proposal and the EPD Transaction; changes
in relevant tax and other laws, including but not limited to
changes in healthcare and pharmaceutical laws and regulations in
the U.S. and abroad; the integration of Perrigo and the EPD
Business being more difficult, time-consuming, or costly than
expected; operating costs, customer loss and business disruption
(including, without limitation, difficulties in maintaining
relationships with employees, customers, clients, or suppliers)
being greater than expected following the Perrigo Proposal and the
EPD Transaction; the retention of certain key employees of Perrigo
and the EPD Business being difficult; the possibility that Mylan
may be unable to achieve expected synergies and operating
efficiencies in connection with the Perrigo Proposal and the EPD
Transaction within the expected time-frames or at all and to
successfully integrate Perrigo and the EPD Business; expected or
targeted future financial and operating performance and results;
challenges to our business and strategic plans posed by the recent
unsolicited business proposal made by Teva Pharmaceutical
Industries Ltd. to acquire all of our outstanding shares; the
capacity to bring new products to market, including but not limited
to where Mylan uses its business judgment and decides to
manufacture, market, and/or sell products, directly or through
third parties, notwithstanding the fact that allegations of patent
infringement(s) have not been finally resolved by the courts (i.e.,
an "at-risk launch"); success of clinical trials and our ability to
execute on new product opportunities; the scope, timing, and
outcome of any ongoing legal proceedings and the impact of any such
proceedings on financial condition, results of operations and/or
cash flows; the ability to protect intellectual property and
preserve intellectual property rights; the effect of any changes in
customer and supplier relationships and customer purchasing
patterns; the ability to attract and retain key personnel; changes
in third- party relationships; the impact of competition; changes
in the economic and financial conditions of the businesses of
Mylan, Perrigo, or the combined company; the inherent challenges,
risks, and costs in identifying, acquiring, and integrating
complementary or strategic acquisitions of other companies,
products or assets and in achieving anticipated synergies;
uncertainties and matters beyond the control of management; and
inherent uncertainties involved in the estimates and judgments used
in the preparation of financial statements, and the providing of
estimates of financial measures, in accordance with accounting
principles generally accepted in the
United States of America and related standards or on an
adjusted basis. For more detailed information on the risks and
uncertainties associated with Mylan's business activities, see the
risks described in Mylan's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2015 and our
other filings with the SEC. These risks, as well as other risks
associated with Mylan, Perrigo, and the combined company are also
more fully discussed in the Preliminary Proxy Statement. You
can access Mylan's filings with the SEC through the SEC website at
www.sec.gov, and Mylan strongly encourages you to do so. Except as
required by applicable law, Mylan undertakes no obligation to
update any statements herein for revisions or changes after the
date of this communication.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-acknowledges-exercise-of-full-call-option-by-the-independent-foundation-300117756.html
SOURCE Mylan N.V.